Short answer: the RSV shot for babies in 2026 is a single dose of nirsevimab, a long-acting antibody that gives immediate protection through the winter season. It is offered to babies entering their first RSV season, with wider second-season cover for higher-risk toddlers after the September 2026 guidance update.
If you are searching “RSV vaccine for babies 2026” in October, you are probably asking three things. What is this shot? Does my baby qualify? And does it actually keep babies out of hospital? Here is what the 2026 programmes and the published evidence say.
What is RSV and why does it matter for babies?
Respiratory syncytial virus, usually shortened to RSV, is a common and highly contagious winter virus. In most adults it causes a mild cold. In babies, especially in their first winter, it can cause bronchiolitis and pneumonia and is a leading cause of infant hospital admission.
The American Academy of Pediatrics, citing Centers for Disease Control and Prevention data, puts the scale plainly: RSV causes about 50,000 to 80,000 hospitalisations each year in United States children under five years. Ireland’s Health Service Executive describes the same pattern for its programme: RSV usually causes mild illness, but it can cause serious illness in babies and young children, particularly during their first winter.
That first-winter risk is why timing matters. Protection given just before or at the start of the season covers the months when RSV circulates most widely.
Is the RSV shot for babies a vaccine?
Strictly, no, and the distinction helps explain how it works. The baby shot used in the 2026 programmes is nirsevimab, described by the HSE as a single dose that gives babies immediate protection during the RSV season.
Nirsevimab is a laboratory-made antibody. A vaccine teaches the body to make its own antibodies over the following weeks. An antibody shot supplies ready-made protection straight away, which is why programmes offer it in maternity hospitals before a newborn goes home, where possible. Parents often search for it as a vaccine, and clinics often call it RSV immunisation. Both phrases point to the same one-dose product.
There is also a separate RSV vaccine given in pregnancy in some countries, intended to pass protection to the baby before birth. The AAP guidance for 2026 to 2027 says infant immunisation is recommended for babies under eight months entering their first season unless the infant already has documented protection from vaccination of their pregnant parent. If you are pregnant or have just given birth, that is a question for your maternity team, because the right route depends on what is offered locally and whether maternal vaccination already took place.
Who can get the RSV shot for babies in 2026?
Eligibility depends on country, so treat the examples below as worked examples and check your local programme. The pattern across programmes is consistent: protect every baby in their first season, then protect higher-risk children again in their second season.
Ireland: who is offered it this winter?
Ireland’s 2026 to 2027 RSV Infant Immunisation Programme started on 1 September 2026. According to the HSE press release of 27 August 2026, free immunisation is offered through maternity hospitals and participating GP practices:
Babies born between 1 September 2026 and 28 February 2027 will be offered RSV immunisation in maternity hospitals before they go home, where possible.
Babies born between 1 March and 31 August 2026 can receive RSV immunisation through participating GP practices.
Babies at higher risk of serious RSV illness will be offered immunisation through a specialist pathway.
The HSE encourages parents of babies born between March and August to arrange immunisation through their GP, ideally before the RSV season, and notes that RSV immunisation can be given safely alongside routine childhood vaccinations, so scheduled vaccines do not need to be delayed.
United States: what changed on 2 September 2026?
The AAP published its 2026 to 2027 RSV policy on 2 September 2026. It continues to recommend RSV immunisation for all infants under eight months of age born during or entering their first RSV season, unless the baby has documented protection from vaccination of their pregnant parent.
The change parents and clinicians noticed is in the second season. For children aged eight through 19 months entering their second RSV season, the AAP expanded the high-risk criteria. The updated groups include children born preterm at less than 32 weeks gestation, regardless of the need for medication or other support; children with haemodynamically significant congenital heart disease; children with anatomic pulmonary abnormalities or neuromuscular disorders that put them at risk for severe RSV disease; and children with Down syndrome or other chromosomal differences placing them at higher risk of severe RSV disease.
In plain language: a healthy toddler usually does not get a second-season dose, but a toddler whose lungs, heart, muscles, chromosomes or early birth history raise the stakes now qualifies under clearer, wider rules in the United States guidance.
What if you are in the UK or elsewhere?
Do not read Ireland’s dates as NHS dates, and do not read AAP guidance as a UK eligibility list. Programmes differ by country and, in some places, by region. The useful takeaway for any parent in October 2026 is the timing principle: if your baby is in their first autumn and winter, ask now rather than waiting for a cough. Your midwife, health visitor, GP or paediatrician can confirm whether your baby is in the current local cohort, whether the maternity hospital or GP route applies, and whether a higher-risk specialist pathway is the right route.
How well does the one-dose shot work?
This is the question that decides whether the programme is worth the appointment, and it is where parents deserve numbers with sources rather than slogans.
In Ireland, the HSE reports that last winter more than 37,000 infants were immunised. Uptake was 88 percent among babies born from September to February who received the immunisation in maternity hospitals, and 100 percent among high-risk infants. The programme reduced RSV-related hospitalisations by 70 percent among babies born during the RSV season. Across eligible groups, the HSE estimates infant immunisation averted over 1,000 emergency department presentations, hospitalisations and intensive care admissions. The HSE also cites international evidence that immunisation is over 80 percent effective in preventing RSV-associated lower respiratory tract infections.
The Galicia study in Spain, published in The Lancet Infectious Diseases, gives the detailed real-world picture behind figures like those. In the NIRSE-GAL population study, 9,408 of 10,259 eligible infants in the seasonal and catch-up groups received nirsevimab. Effectiveness against hospitalisation for RSV-related lower respiratory tract infection was 82.0 percent, with a 95 percent confidence interval of 65.6 to 90.2. Effectiveness against severe RSV-related infection requiring oxygen support was 86.9 percent. Overall, RSV-related lower respiratory tract hospitalisations were reduced by 89.8 percent, and the number needed to immunise to avoid one hospitalisation was 25.
United States surveillance tells a similar story. A CDC-led study across seven paediatric centres, published in JAMA Pediatrics, evaluated the 2023 to 2024 season and found nirsevimab was 89 percent effective against medically attended RSV-associated acute respiratory illness and 93 percent effective against RSV-associated hospitalisation, although only 442 infants in that analysis had received the product, so the hospitalisation estimate rests on a smaller treated group.
The randomised HARMONIE trial, published in the New England Journal of Medicine in 2023, tested a single intramuscular dose of nirsevimab against standard care in infants entering their first RSV season in France, Germany and the United Kingdom. Hospitalisation for RSV-associated lower respiratory tract infection occurred in 0.3 percent of the nirsevimab group and 1.5 percent of the standard care group, corresponding to 83.2 percent efficacy. Very severe RSV-associated infection occurred in 0.1 percent and 0.5 percent respectively, corresponding to 75.7 percent efficacy.
Read together, the honest summary is this: one dose does not make RSV disappear, and no programme claims that. Across a randomised trial, a large Spanish population rollout and United States surveillance, the reduction in hospital care is consistently large, roughly eight to nine out of ten hospitalisations prevented in the groups studied, with Ireland reporting a 70 percent fall in hospitalisations among season-born babies in its own programme last winter. Differences between those figures reflect different populations, seasons and methods, not a contradiction.
When should the shot be given?
Before the season does its worst. Ireland’s programme opened on 1 September 2026, ahead of autumn and winter circulation. The HSE’s advice is to get immunisation as early as possible in the RSV season so protection covers the period when RSV is circulating at highest levels. For babies born during the season, maternity-hospital offer before going home is designed to close the gap between birth and first exposure at home, where older siblings and visitors can bring winter viruses through the door.
If your baby was born between March and August and your local route is a GP practice, October is not too late to ask, but it is late enough that you should not leave it to a routine review months away. If your child is entering a second season and has any of the higher-risk features listed in the AAP update, raise it explicitly, because second-season eligibility is narrower and easier to miss.
What are the side effects and practical points?
Parents usually ask whether the shot can be given with other vaccines and what happens afterwards. On the practical point, the HSE states RSV immunisation can safely be given alongside routine childhood vaccinations, and parents do not need to delay scheduled vaccinations. For individual side-effect counselling, the product information and your clinician are the right source, because advice must reflect your baby’s history. As with any immunisation appointment, tell the team about previous reactions, current illness and medicines before the dose is given.
One more practical point matters in 2026. Because the shot is an antibody rather than a traditional vaccine, protection is immediate but seasonal. It is designed to cover the first autumn and winter, not to replace the routine childhood vaccine schedule. Keep every routine appointment unless your clinician advises otherwise.
What should parents do this week?
If your baby was born from 1 September 2026, ask the maternity unit whether the dose was given or is planned before discharge. If your baby was born between March and August 2026 and you are in Ireland, contact a participating GP practice and ask about the RSV immunisation appointment. If your baby is under eight months entering a first season elsewhere, ask your paediatrician or family doctor what the local first-season offer is and whether maternal vaccination changes the plan. If your child is eight to 19 months and was born before 32 weeks, has significant congenital heart disease, has an anatomic lung abnormality or neuromuscular disorder, or has Down syndrome or another chromosomal difference, ask specifically about second-season eligibility.
And if your baby develops breathing difficulty, poor feeding or unusual sleepiness, seek urgent medical care regardless of immunisation status. The shot sharply lowers hospital risk. It does not turn a worrying symptom into a wait-and-see symptom.
Frequently asked questions
Is nirsevimab a vaccine?
No. Nirsevimab is a long-acting monoclonal antibody. It provides ready-made antibodies for the RSV season rather than training the baby’s immune system in the way a traditional vaccine does. Programmes call it RSV immunisation, which is why the search phrase “RSV vaccine for babies 2026” usually leads to nirsevimab.
How many doses does a baby need?
For the first RSV season, the programmes described here use a single dose of nirsevimab. Children who qualify in their second season because of higher-risk conditions are assessed separately. In United States guidance, the second-season product and dose are for eligible higher-risk children only.
Does the RSV shot stop all RSV infections?
No. The evidence measures severe outcomes, mainly hospitalisation and medically attended lower respiratory illness. In Galicia, effectiveness against RSV hospitalisation was 82.0 percent, and RSV hospitalisations fell by 89.8 percent overall. In Ireland, hospitalisations among season-born babies fell by 70 percent last winter. Many immunised babies may still catch a mild cold-like illness.
Can the RSV shot be given with routine vaccines?
Yes, according to the HSE. RSV immunisation can be given safely alongside routine childhood vaccinations, and parents are advised not to delay scheduled vaccinations. Confirm the exact appointment plan with your GP or maternity team.
Who counts as higher risk in the second season?
Under the AAP update of 2 September 2026, children aged eight through 19 months entering their second season include those born preterm at less than 32 weeks, those with haemodynamically significant congenital heart disease, those with anatomic pulmonary abnormalities or neuromuscular disorders, and those with Down syndrome or other chromosomal differences at higher risk. Other established high-risk groups, such as severe immunocompromise and certain lung conditions, also appear in the full guidance. Local programmes may use a specialist pathway.
When is RSV season?
RSV is a winter virus that circulates most widely through autumn and winter. Ireland opened its 2026 to 2027 programme on 1 September 2026 so babies are protected before and during that peak. If you are reading this in October, ask now.
Sources: AAP press release, 2 September 2026; HSE press release, 27 August 2026; NIRSE-GAL, The Lancet Infectious Diseases 2024; CDC JAMA Pediatrics surveillance 2023 to 2024; Drysdale et al., HARMONIE, New England Journal of Medicine 2023.
